Dr. Alison Long MD, Ph.D has 18 years’ experience working in the pharmaceutical and biotechnology industry, and a proven track record developing therapies, which includes securing six new drug approvals and twelve Investigational New Drug (IND) approvals over her career. She has worked on small and large molecules across all phases of development, and more recently on programs investigating advanced therapies including a liver-directed antigen specific immune tolerance compound and multiple gene therapy approaches. Dr. Long most recently served as Chief Medical Officer at Anokion, Inc. and prior to that at Kaleido Biosciences where she was responsible for the clinical development, clinical operations, medical affairs, and biostatistics functions behind Kaleido’s development programs. Previously Dr. Long was Interim Chief Medical Officer at Freeline Therapeutics, where she oversaw the scientific and clinical development of all programs, including gene therapy in hemophilia B, Fabry and Gaucher’s disease. Dr. Long has also served in roles of increasing responsibility at Spark Therapeutics, uniQure, Aegerion Pharmaceuticals, Galderma and Biogen, where she focused on the development and subsequent EU approval of Elocta®. Prior to her executive positions, Dr. Long was a physician scientist at AFG Biosolutions and Brain Chemistry Labs, following 12 years in private internal medicine practice in Johannesburg, South Africa. Dr. Long earned her medical degree from the University of the Witwatersrand in South Africa, and a Ph.D. in Medical Biodefense from George Mason University in Fairfax, VA.
Leadership
